AIM: To evaluate the 5-lipoxygenases (Loxs) expression level in human colorectal cancer specimens in order to determine its clinicopathologic significance in human tumorigenesis. METHODS: The relative quantity of 5-Lox mRNA in paired 91 colorectal tumor and adjacent normal mucosa samples was determined by real time quantitative PCR. Additionally, the expression of 5-Lox and cyclooxygenase (Cox)-2 proteins was also examined using immunohistochemical staining methods. RESULTS: There was a marked increase in 5-Lox mRNA levels in the tumor compared with paired normal mucosa samples (P < 0.0001). Sixty six (72.5%) tumors showed high 5-Lox mRNA levels. The positivity rate of 5-Lox and Cox-2 protein expression was 68.7% and 79.1% respectively. There was a significant association between tumoral 5-Lox mRNA level and tumor size (Rho = 0.392, P = 0.0002), depth or vessel invasion. CONCLUSION: These results suggest that 5-Lox is up-regulated in colorectal cancer and that inhibition of its expression might be valuable in the prevention and treatment of colorectal cancer.
AIM: To evaluate the 5-lipoxygenases (Loxs) expression level in humancolorectal cancer specimens in order to determine its clinicopathologic significance in human tumorigenesis. METHODS: The relative quantity of 5-Lox mRNA in paired 91 colorectal tumor and adjacent normal mucosa samples was determined by real time quantitative PCR. Additionally, the expression of 5-Lox and cyclooxygenase (Cox)-2 proteins was also examined using immunohistochemical staining methods. RESULTS: There was a marked increase in 5-Lox mRNA levels in the tumor compared with paired normal mucosa samples (P < 0.0001). Sixty six (72.5%) tumors showed high 5-Lox mRNA levels. The positivity rate of 5-Lox and Cox-2 protein expression was 68.7% and 79.1% respectively. There was a significant association between tumoral 5-Lox mRNA level and tumor size (Rho = 0.392, P = 0.0002), depth or vessel invasion. CONCLUSION: These results suggest that 5-Lox is up-regulated in colorectal cancer and that inhibition of its expression might be valuable in the prevention and treatment of colorectal cancer.
Authors: I Shureiqi; K J Wojno; J A Poore; R G Reddy; M J Moussalli; S A Spindler; J K Greenson; D Normolle; A A Hasan; T S Lawrence; D E Brenner Journal: Carcinogenesis Date: 1999-10 Impact factor: 4.944
Authors: P C Chulada; M B Thompson; J F Mahler; C M Doyle; B W Gaul; C Lee; H F Tiano; S G Morham; O Smithies; R Langenbach Journal: Cancer Res Date: 2000-09-01 Impact factor: 12.701
Authors: David A Reardon; Jennifer A Quinn; James Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Michael Badruddoja; James E Herndon; Jeannette M Dowell; Allan H Friedman; Henry S Friedman Journal: Cancer Date: 2005-01-15 Impact factor: 6.860
Authors: Suzanna M Zick; D Kim Turgeon; Jianwei Ren; Mack T Ruffin; Benjamin D Wright; Ananda Sen; Zora Djuric; Dean E Brenner Journal: Mol Carcinog Date: 2014-04-24 Impact factor: 4.784
Authors: Altaf Mohammed; Naveena B Janakiram; Qian Li; Chang-In Choi; Yuting Zhang; Vernon E Steele; Chinthalapally V Rao Journal: Cancer Prev Res (Phila) Date: 2011-09-01
Authors: Suzanna M Zick; D Kim Turgeon; Shaiju K Vareed; Mack T Ruffin; Amie J Litzinger; Benjamin D Wright; Sara Alrawi; Daniel P Normolle; Zora Djuric; Dean E Brenner Journal: Cancer Prev Res (Phila) Date: 2011-10-11
Authors: Suniti Misra; Shibnath Ghatak; Alok Vyas; Paul O'Brien; Roger R Markwald; Madhukar Khetmalas; Vincent C Hascall; James B McCarthy; Nikos K Karamanos; Markku I Tammi; Raija H Tammi; Glenn D Prestwitch; Subhash Padhye Journal: Med Chem Res Date: 2014-08-01 Impact factor: 1.965